In Phase I\/II trial of durvalumab with neoadjuvant chemo, pathological complete response rates similar for Black, non-Black patients<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Aug. 19, 2022 (HealthDay News) — Among patients with early-stage triple-negative breast cancer (TNBC), the pathologic complete response (pCR) rate for durvalumab added to neoadjuvant chemotherapy is 46 percent, with similar rates for African American (AA) and non-AA patients, according to a study published online July 29 in Clinical Cancer Research<\/em>.<\/p>\n Julia Foldi, M.D., Ph.D., from the Yale University School of Medicine in New Haven, Connecticut, and colleagues examined the safety and efficacy of durvalumab concurrent with neoadjuvant chemotherapy for stage I to III TNBC by race in a study involving 67 patients. pCR was assessed as the primary efficacy end point.<\/p>\n Twenty-one of the patients self-identified as AA (31 percent). The researchers found no significant associations between race and baseline tumor stage, programmed death-ligand 1 status, or stromal tumor-infiltrating lymphocyte count. The pCR rate was 46 percent overall, with similar rates for AA and non-AA patients (43 and 48 percent, respectively). In non-AA and AA patients, the three-year event-free survival rates were 78.3 and 71.4 percent, respectively, and three-year overall survival was 87 and 81 percent, respectively; the differences were not statistically significant. Incidences of immune-related adverse events were similar for AA and non-AA patients.<\/p>\n “These results suggest that when patients receive identical treatment and are monitored closely, disparities in outcomes can be mitigated or even abolished,” the authors write.<\/strong><\/p>\n Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca, which manufactures durvalumab and funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n